Related Experiment Video
Updated: Mar 29, 2026
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
APC methylation predicts biochemical recurrence of patients with prostate cancer: a meta-analysis
Yi Wang1, Caibin Fan2, Jiang Yu1
1Department of Urology, The Suzhou Kowloon Hospital Affiliated to Shanghai Jiaotong University, Medical School Suzhou 215021, Jiangsu Province, China.
Abstract:
The promoter region of adenomatous polyposis coli (APC) has been found to be frequently methylated in prostate cancer. However, the prognostic role of APC methylation in prostate cancer was still debated. We performed a meta-analysis by searching PubMed and EMBASE databases. Pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CI) were calculated. Seven studies (1227 patients) were included in this study. After calculation, the overall HR was 1.74 (95% CI: 1.31-2.31), implicating that APC methylation has an unfavorable impact on biochemical recurrence of prostate cancer. A subgroup analysis was performed with detection method, combined HR was 1.53 (95% CI: 1.19-1.96) for Methylation-Specific PCR (MSP), and 2.08 (95% CI: 1.18-3.64) for quantitative Methylation-Specific PCR (qMSP). Another subgroup analysis was conducted according to regions of the patients, combined HR was 2.02 (95% CI: 1.18-3.49) for North America, and 1.64 (95% CI: 1.14-2.36) for European. In conclusion, APC methylation is associated with biochemical recurrence of patients with prostate cancer.
